FiercePharma3h
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
Monthly Prescribing Reference3h
Neoadjuvant/Adjuvant Opdivo Approved for Resectable NSCLC
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
Medscape3h
Nivolumab NSCLC Approval Expanded to Perioperative Setting
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with resectable NSCLC.
Cure Today7h
FDA Approves Presurgical, Postsurgical Opdivo for NSCLC
The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.
ENDPOINTS NEWS7h
Op­di­vo gets FDA ap­proval for use around lung can­cer surgery fol­low­ing Keytru­da and Imfinzi
The FDA greenlighted Bristol Myers Squibb’s Opdivo for use before and after surgery for non-small cell lung cancer. A regimen ...
Bristol-Myers wins FDA nod for Opdivo lung cancer indication
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
Targeted Oncology8h
FDA Approves Perioperative Nivolumab in Resectable NSCLC
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...